Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors

Gurleen Kaur1 and Emily Lau2

Abstract
Heart failure with preserved ejection fraction has a higher prevalence in women versus men. There are several proposed mechanisms to explain this sex discrepancy including differences in cardiovascular adaptation to comorbidities and potential underlying etiologic mechanisms. In this review, we summarize sex differences in traditional risk factors, such as obesity, diabetes, hypertension, and coronary artery disease, which contribute to the development of heart failure with preserved ejection fraction in women. Furthermore, we explore female-specific risk factors, such as sex hormones, adverse pregnancy outcomes, and other reproductive factors, which may explain the predominance of heart failure with preserved ejection fraction in women. Beyond sex differences in risk factors, there are also significant sex differences in outcomes with women reporting lower quality of life but overall better survival versus men. Finally, while treatment options for patients with heart failure with preserved ejection fraction are still limited, sex differences have also been reported for the available therapies, with suggestion of preferential benefit of specific heart failure with preserved ejection fraction therapies in women. Further work is required to better understand sex differences in heart failure with preserved ejection fraction, including deeper understanding of pathophysiological mechanisms, derivation of more accurate risk stratification models, and increased representation of women in clinical trials.

Keywords
heart failure, HFrEF, sex differences

Date received: 23 June 2022; revised: 1 October 2022; accepted: 2 November 2022

Introduction
Heart failure (HF) affects approximately six million Americans above the age of 20, with a projected prevalence of more than eight million by 2030.1,2 HF encompasses a broad range of phenotypes and is further subdivided into HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFrEF), both of which have unique epidemiology, risk factors, and treatment options. Secular trends from the Framingham Heart Study have demonstrated a declining incidence for HFrEF, but an increasing incidence for HFrEF over two decades (1990–1999 versus 2000–2009).1 Significant sex differences exist in the realm of HF, particularly when considering HFrEF. For example, the odds of HFrEF were 2.8-fold higher in women than in men within the Framingham Heart Study.3,4 The prevalence of HFrEF has also been demonstrated to be higher in women and increases with age (8%–10% in women and 4%–6% in men for individuals ≥ 80 years of age).5 Epidemiologic analyses from large

1Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
2Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA

Corresponding author:
Emily Lau, Division of Cardiology, Massachusetts General Hospital, 185 Cambridge Street, CPZN #3206, Boston, MA 02114, USA.
Email: elau6@mgh.harvard.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
registries found that women comprise 55% of patients with HFP EF, but only 29% of patients with HFrEF.6

There is no clear consensus on the exact pathophysiological mechanisms to explain sex differences in prevalence, but hypotheses include greater inflammation and chronic microvascular dysfunction in women, two purported mechanistic drivers of HFP EF (Figure 1).7,8 Furthermore, traditional risk factors (obesity, diabetes, hypertension, and coronary artery disease (CAD)) preferentially contribute to development of HFP EF in women, and emerging data show that sex-specific risk factors including early menopause, adverse pregnancy outcomes (APOs), and other reproductive factors are also important risk factors for HFP EF in women. Finally, HFP EF is a clinical syndrome with considerable phenotypic heterogeneity, in part related to differences in patient profiles in men versus women. For example, previous studies have demonstrated notable phenotypic differences based on sex—women have more concentric left ventricular (LV) remodeling and more severe diastolic dysfunction with impaired LV relaxation versus men.9,10 A previous study analyzing data from three large HFP EF trials showed age-related differences in HFP EF: Younger patients were more often obese men and older patients were more often women with higher prevalence of comorbidities.11 Novel phenotyping tools are now able to identify distinct groups of HFP EF patients that differ in risk profile, outcomes, and clinical trajectories. One study leveraging these novel phenotyping tools found three separate phenogroups among a US-based cohort of 397 patients with HFP EF: (1) younger females with less

---

**Figure 1.** Risk factors and pathophysiology for HFP EF in women. Summary of proposed pathophysiological mechanisms for HFP EF in women, including oxidative stress, vascular dysfunction, systemic inflammation, and myocardial dysfunction. Summary of traditional and sex-specific risk factors for HFP EF in women. HFP EF: heart failure with preserved ejection fraction; RAAS: renin angiotensin aldosterone system; LV: left ventricular; CAD: coronary artery disease; SHBG: sex hormone binding globulin; HDP: hypertensive disorders of pregnancy.
adverse remodeling, (2) predominately females with obesity and diabetes, and (3) older men and women with chronic kidney disease and adverse LV remodeling.12 Beyond the sex differences in prevalence and clinical profile, there are also sex differences in outcomes within the HFpEF population, with women reporting lower quality of life (QOL) as compared to men13 but overall better survival.14

In this review, we summarize sex differences in traditional risk factors and explore female-specific risk factors, which may explain the predominance of HFpEF in women. We also review sex differences in outcomes and response to treatment options, while acknowledging existing gaps in knowledge and areas for future research.

**Sex differences in traditional risk factors for HFpEF**

Prediction models from longitudinal community-based cohorts have demonstrated important risk factors for the development of HFpEF including age, blood pressure, body mass index (BMI), and previous myocardial infarction (MI).15 Given that inflammation is thought to be central to the development of HFpEF, sex differences in prevalence of comorbidities that drive inflammation such as obesity, diabetes mellitus, and hypertension may explain the disproportionate risk in women.16,17 Cardiovascular risk factors are strongly associated with incident HF—both HFpEF and HFrEF—in both women and men, as demonstrated by a large analysis compiling data from four community-based cohorts; however, in this analysis, there were subtle sex-related differences with age (women: hazard ratio (HR) 2.07 (95% confidence interval (CI): 1.89–2.28) versus men: HR 1.80 (95% CI: 1.67–1.95)) and hypertension (women: HR 1.98 (95% CI: 1.68–2.34) versus men: HR 1.67 (95% CI: 1.45–1.93)) more strongly associated with HF risk in women.18 In this section, we review important differences between women and men in both the prevalence and the overall HFpEF risk conferred by traditional risk factors (Figure 1).

**Obesity**

Obesity has been an established risk factor for HF for many decades,19 and more recently has been associated with the risk of HFpEF in particular.15,16,20 Obesity is more common among women than men with existing HFpEF (46% versus 35%), as seen in baseline data from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.21 It is also more strongly associated with risk of HFpEF. In a study of 22,681 patients, obesity was more strongly linked with the risk of HFpEF than HFrEF (HR 1.34 per 1 standard deviation increase in BMI (95% CI: 1.24–1.45) versus HR 1.18 (95% CI: 1.10–1.27)), and notably, this association was more pronounced among women versus men (p for difference HFpEF versus HFrEF = 0.01 in women and p = 0.34 in men).22 The proposed model for the relationship between obesity and HFpEF includes cardiometabolic factors, such as insulin resistance, leading to a state of systemic inflammation, endothelial dysfunction, and subsequent myocyte remodeling.23 Furthermore, the relative distribution of fat mass differs between women and men. Pre-menopausal women have more subcutaneous adiposity and less visceral adiposity than men.24 However, during the peri-menopausal transition, there is a rise in visceral adiposity due to the decline in estrogen levels.25 Estrogen may mediate signaling pathways that attenuate reactive oxygen species leading to downstream anti-inflammatory effects. Furthermore, estrogen may exert regulatory effects on adipocyte and cardiomyocyte gene expression at the post-transcriptional level by driving expression of non-coding ribonucleotide acids (RNA), such as microRNAs (miRNAs) and long-non-coding RNAs.26 Therefore, a decline in estrogen levels during menopause may result in loss of protective miRNAs and contribute to a state of systemic inflammation.26

Visceral adipose tissue, in particular, is associated with concentric LV remodeling27 and can also affect exercise intolerance which is a hallmark symptom of HFpEF. Haykowsky et al.28 found that intra-abdominal fat was significantly higher in patients with HFpEF when compared with healthy controls and was the strongest predictor of peak oxygen consumption (a marker of exercise performance). There were inverse associations between intra-abdominal fat with all measurements of physical function, including peak oxygen consumption and 6-min walk distance. This highlights the importance of specific management strategies aimed at not only promoting weight loss in general but also targeting specific fat stores, especially intra-abdominal.

**Diabetes mellitus**

Diabetes mellitus is another traditional risk factor that has been established as having a more pronounced effect on HF in women as compared to men, with a fivefold associated increase in risk in women versus 2.4-fold increase in risk in men.29 The prevailing HFpEF hypothesis proposes that diabetes and other cardiometabolic risk factors contribute to HFpEF pathogenesis via systemic vascular inflammation and endothelial dysfunction.30 The production of reactive oxygen species31 and decreased bioavailability of nitric oxide leads to downstream lowering of soluble guanylate cyclase and protein kinase G (PKG) activity in cardiomyocytes. Deficient PKG activity subsequently impairs myocardial relaxation and induces cardiomyocyte hypertrophy.25 This process appears to occur earlier in the disease course in women versus men.33 Metabolic syndrome, thought to be a clinical precursor to
diabetes, has been shown to be associated with echocardiographic measures of diastolic dysfunction.\textsuperscript{8,34}

**Hypertension**

Hypertension is more prevalent among females with HFrEF versus males, especially in individuals age 75 years or older,\textsuperscript{14} and also confers greater risk of HF in women (threefold increase in risk in women versus twofold increase in men).\textsuperscript{35} Potential explanations include differential remodeling in these two populations. Hypertension more frequently leads to concentric hypertrophy in women, but eccentric remodeling in men.\textsuperscript{36,37} There are also intrinsic physiological characteristics in women that predispose them to HFrEF, including increased arterial stiffness and more pronounced age-related increase in arterial stiffness.\textsuperscript{9,38} In an analysis of 279 participants from the Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection fraction (PARAMOUNT) study, women had higher arterial stiffness compared with men, though the difference was not significant after adjusting for height.\textsuperscript{38} In addition, Higashi et al.\textsuperscript{39} investigated the relationship between arterial stiffness and LV diastolic dysfunction in 446 participants and found higher carotid augmentation index (a parameter of arterial stiffness) was more strongly correlated with measures of LV diastolic function in women than men, even after controlling for confounding factors such as age and blood pressure. Overall, this hints toward a differential impact of aging and hypertension on cardiac structure and endothelial function between the sexes. Augmentation of blood pressure due to arterial stiffness increases LV systolic load and cardiac afterload, therefore, worsening myocardial oxygen demand, all of which can influence LV diastolic function. Additionally, elderly women with isolated systolic hypertension have sex-specific alterations of pulse wave reflection (related to increased LV systolic load) and LV remodeling, which may amplify the increased risk of HFrEF.\textsuperscript{40} Another study reported greater difference between central and peripheral blood pressure, or a higher augmentation index, in women compared to men (7.4 ± 5.2 vs 1.0 ± 6.9; p < 0.001), which may put women at a higher risk for end-organ damage such as LV hypertrophy.\textsuperscript{41}

While hypertension contributes to HFrEF development via concentric hypertrophic in response to increased myocardial afterload, it has also been linked to increased microvascular inflammation which is known to promote downstream myocardial remodeling associated with HFrEF.\textsuperscript{30}

**Coronary artery disease**

CAD and myocardial ischemia can lead to diastolic dysfunction and HFrEF. In a retrospective study of 376 patients with HFrEF, those with CAD were more likely to be men as compared to those without CAD (57% versus 25%).\textsuperscript{52} Several studies, including the I-PRESERVE study and the PARAMOUNT study, have demonstrated that women are less likely to have CAD versus men (38% versus 43% stable angina in I-PRESERVE and 22% versus 11% MI in PARAMOUNT).\textsuperscript{21,38} However, women are more likely to have non-obstructive CAD and coronary microvascular dysfunction, which has a high prevalence in HFrEF.\textsuperscript{7,43} In Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction, a prospective, multi-center study comprised of 263 patients, the prevalence of coronary microvascular dysfunction in HFrEF patients was 75% and was associated with systemic endothelial dysfunction as measured by peripheral arterial tonometry testing.\textsuperscript{7} Furthermore, in a study of 201 patients without obstructive CAD, impaired coronary flow reserve (a marker of chronic microvascular dysfunction) was associated with diastolic dysfunction (adjusted odds ratio (OR) 2.58, 95% CI: 1.22-5.48) and HFrEF hospitalizations (adjusted HR 2.47, 95% CI: 1.09-5.62).\textsuperscript{44} Finally, an analysis from the Multiethnic Study of Atherosclerosis (MESA), comprised of 6,809 healthy participants, reported that coronary artery calcium (CAC) scores greater than 300 were associated with increased risk of HFrEF, but only in women.\textsuperscript{45} Notably, after excluding participants who developed coronary heart disease events before HFrEF hospitalization, CAC greater than 300 was no longer a significant contributor to estimating risk of HFrEF in women, suggesting that ischemia and microvascular dysfunction may be mediators in women.\textsuperscript{45}

**Atrial fibrillation**

Atrial fibrillation (AF) is prevalent in 25%–39% of HFrEF patients, and the two conditions share common risk factors including age and hypertension.\textsuperscript{46} Studies have also demonstrated an association between AF with death and HF hospitalization in HFrEF patients, an association that has not been observed in HFrEF patients.\textsuperscript{57} While AF is more common in men versus women with HFrEF, outcomes are worse in women with HFrEF and AF. For example, among participants enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, the association between AF and hospitalization was stronger in women with HFrEF (HR 1.63, 95% CI: 1.40–1.91) versus men (HR 1.37, 95% CI: 1.18–1.58), p-interaction = 0.032.\textsuperscript{48}

**Iron deficiency and anemia**

Anemia is a common comorbidity in HF and has been independently associated with greater risk of death and HF hospitalization across a range of ejection fractions.\textsuperscript{49,50} Potential mechanisms include adverse LV remodeling,
neurohormonal activation, and higher levels of systemic inflammation. Previous studies have shown a prevalence of 21%–68% within the HFpEF population, with higher prevalence is HFpEF than HFrEF. Within the Get With the Guidelines-Heart Failure registry, prevalence of anemia was higher in women versus men for both HFrEF and HFpEF subgroups. Greater prevalence of iron deficiency in women in the general population has been hypothesized to predispose to HFpEF due to adverse effects on oxidative metabolism and immunological responses. Furthermore, in the Acute Decompensated Heart Failure Syndromes registry in Japan, there were sex-specific differences in the association between anemia and outcomes. Anemia was an independent predictor of all-cause death and cardiac death in women with HFpEF, but not in women with HFrEF, while the opposite was observed in men.

**Female-specific risk factors**

Beyond sex differences in prevalence and conferred risk related to traditional risk factors, emerging data suggest that sex-specific risk factors may also contribute to the predominance of HFpEF in women (Figure 1).

**Sex hormones**

Patients with HFpEF are more likely to be older females, with postmenopausal women having a higher incidence of LV diastolic dysfunction. This observation has led to the hypothesis that the decline in estradiol at menopause may contribute to the pathogenesis of HFpEF. Estradiol is an important regulator of inflammation, reactive oxygen species, nitric oxide signaling, and endothelial function. The decline in estradiol levels at menopause is associated with changes in body fat, blood pressure, and lipids, all of which are implicated in development of HFpEF. Furthermore, in a study from MESA, a more androgenic pattern of hormones with lower estradiol, higher free testosterone, and lower sex hormone binding globulin was associated with greater increase in LV mass in both women and men, but associated with concentric remodeling only in women.

**Pregnancy**

Hypertensive disorders of pregnancy, such as preeclampsia, are risk factors for future cardiovascular disease including HFpEF. In a meta-analysis of twenty-two studies, preeclampsia was associated with a fourfold increase in future incident HF. Furthermore, in a Norwegian cohort study, preeclampsia was associated with HF with HR of 2 (95% CI: 1.50–2.68, p < 0.001). While most previous studies did not distinguish between HFrEF and HFpEF, a recent retrospective cohort study utilizing New York and Florida state data found that preeclampsia was independently associated with greater risk of HFpEF with an adjusted HR of 2.09 (95% CI: 1.80–2.44). Additionally, there is likely to be reciprocal interplay between traditional cardiovascular risk factors and sex-specific risk factors. For example, women with preexisting hypertension and diabetes are at increased risk of developing preeclampsia, and patients with preeclampsia are more likely to develop downstream hypertension and diabetes. Preeclampsia and resultant endothelial dysfunction can lead to diastolic dysfunction that persists up to 1 year postpartum in 51% of patients, highlighting the importance of identifying and monitoring these high-risk women for downstream cardiovascular complications. Endothelial dysfunction with low nitric oxide bioavailability and LV remodeling is the leading hypothesis explaining these associations. Breetveld et al. reported that women with former preeclampsia have lower endothelium-dependent flow-mediated dilation, a marker of endothelial dysfunction, compared with women with normal gestation along with threefold higher prevalence of HF. Another study demonstrated impaired coronary flow reserve in patients with preeclampsia. In addition, evidence of persisting vascular dysfunction has been described in women following pregnancy complicated by hypertensive disorder of pregnancy.

**Reproductive factors**

Other pregnancy-related features, including parity, are also associated with diastolic function. A study of 710 women
demonstrated grand parity, which was defined as greater than four births, to be an independent risk factor for LV diastolic dysfunction. The exact mechanism remains to be elucidated.74 On the other hand, studies focused on the TOPCAT trial showed no difference in cardiovascular outcomes between women and men, though women had worse age-adjusted outcomes.79 Other studies have also demonstrated lower QOL in women with HFpEF, which is independent of age and HF severity.80

One potential explanation for worse QOL in women versus men with HFpEF is that women have lower exercise capacity, which is a quintessential feature of HFpEF. In a study of participants from the RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) trial, women with HFpEF had worse exercise capacity than men, despite comparable resting cardiac function.81 Furthermore, a cross-sectional observational study using invasive hemodynamic exercise measures demonstrated that women have lower exercise peripheral oxygen extraction and ventricular reserve compared to men in spite of lower burden of cardiometabolic disease among women in that study’s population.82 Additionally, Beale et al.9 revealed that women had poorer diastolic reserve with higher measurements of LV filling pressures with exercise as well as systemic and pulmonary vascular dysfunction in a group of 161 patients with HFpEF. These sex differences in exercise hemodynamics highlight the need for further investigation into related pathophysiology to explain differences in muscle and vascular responses to exercise in women versus men with HFpEF.

While exercise capacity may be one explanation to explain variances in QOL, another study demonstrated no association between exercise capacity with QOL in women with HFpEF. In this study which examined echocardiographic and QOL data from the RELAX and NEAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trials in men versus women, diastolic dysfunction, ischemic heart disease, and exercise capacity predicted QOL in men with HFpEF, while only age and BMI predicted QOL for women. More investigation is required to ascertain these differences, including potential contributions from psychosocial factors and other social determinants of health.83

### Sex differences in outcomes

Studies have shown HFpEF outcomes differ by sex. In general, women with HFpEF have better outcomes than men,21,78 including lower in-hospital mortality (4.2% versus 4.6%, p < 0.01).14 However, a post hoc analysis of the TOPCAT trial showed no difference in cardiovascular and all-cause mortality between women and men, though women had worse patient-reported outcomes.79 Other studies have also demonstrated lower QOL in women with HFpEF, which is independent of age and HF severity.80

One potential explanation for worse QOL in women versus men with HFpEF is that women have lower exercise capacity, which is a quintessential feature of HFpEF. In a study of participants from the RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) trial, women with HFpEF had worse exercise capacity than men, despite comparable resting cardiac function.81 Furthermore, a cross-sectional observational study using invasive hemodynamic exercise measures demonstrated that women have lower exercise peripheral oxygen extraction and ventricular reserve compared to men in spite of lower burden of cardiometabolic disease among women in that study’s population.82 Additionally, Beale et al.9 revealed that women had poorer diastolic reserve with higher measurements of LV filling pressures with exercise as well as systemic and pulmonary vascular dysfunction in a group of 161 patients with HFpEF. These sex differences in exercise hemodynamics highlight the need for further investigation into related pathophysiology to explain differences in muscle and vascular responses to exercise in women versus men with HFpEF.

While exercise capacity may be one explanation to explain variances in QOL, another study demonstrated no association between exercise capacity with QOL in women with HFpEF. In this study which examined echocardiographic and QOL data from the RELAX and NEAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trials in men versus women, diastolic dysfunction, ischemic heart disease, and exercise capacity predicted QOL in men with HFpEF, while only age and BMI predicted QOL for women. More investigation is required to ascertain these differences, including potential contributions from psychosocial factors and other social determinants of health.83

### Sex differences in treatment

While treatment options for HFpEF are not as widespread as for HFREF, sex differences have been reported for the available HFpEF therapies (Table 1). In a post hoc analysis of the TOPCAT trial, there was a reduction in all-cause mortality for spironolactone in women (HR 0.66; 95% CI: 0.48–0.9; p = 0.01), but not in men (sex–treatment interaction p = 0.02). These results were only hypothesis generating, but warrant further studies on the use of spironolactone in women with HFpEF. The authors of the analysis hypothesized that differential effects of mineralocorticoid antagonists on cardiac remodeling in women versus men may have explained the sex-specific finding.79 In a prespecified subgroup analysis of the Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction trial, sacubitril-valsartan reduced the risk of HF hospitalization by 26% in women, but no effect was seen in men.84,85 Similar to TOPCAT, there is no clear mechanistic evidence to explain these findings, but sex differences in natriuretic peptide (NP) biology and crosstalk with sex hormones have been proposed.86 Specifically, the authors hypothesize that sacubitril-valsartan-induced NP production may preferentially benefit women versus men with HFpEF given lower baseline levels of NP in women with HFpEF.85 Lower NP levels are associated with reduced cyclic guanosine monophosphate-protein kinase (cGMP) signaling. This reduction in signaling may be further accentuated by loss of estrogen-dependent endothelial nitric oxide synthase activation of cGMP pathway following menopause. NP activation by sacubitril-valsartan may explain preferential benefit in women with HFpEF who are cGMP deficient. Sodium glucose transporter-2 inhibitors (SGLT2i) are another class of medications that have emerged as treatment options for HFpEF. SGLT2i do not lead to NP activation, but rather work through several distinct mechanisms. Most recently, in the EMPEROR-PRESERVED (Empagliflozin in Heart Failure with a Preserved Ejection Fraction) trial and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial, which investigated the SGLT2 inhibitors empagliflozin and dapagliflozin, respectively, there was no difference in treatment effect among women versus men.86,87

### Conclusion and gaps in knowledge

The disproportionate prevalence of HFpEF in women stems from a myriad of factors, including higher rates of...
Table 1. Sex differences in recent HFpEF treatment trials.

| Trial (year)        | Number of patients | % female | Intervention         | EF cut-off | Type of analysis | Baseline differences (women versus men)                                      | Sex-specific results                                                                                                                                                                                                 |
|---------------------|--------------------|----------|----------------------|------------|------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TOPCAT (2019)       | 1767               | 49.9%    | Spironolactone       | 45%        | Post hoc, non-pre-specified                                                | Older Fewer comorbidities Higher LVEF, BP, BMI Lower GFR, Hgb Higher NYHA class Lower KCCQ score                                                                                                                                   | • Rates of primary outcome and HF hospitalization not different  
  • Significant reduction in all-cause mortality w/ spironolactone in women (HR 0.66; 95% CI: 0.48–0.9; p = 0.01), but not in men; sex-treatment interaction p = 0.024. |
| PARAGON-HF (2020)   | 4796               | 51.7%    | Sacubitril-valsartan | 45%        | Prespecified subgroup                                                     | Older More obesity Fewer comorbidities Lower median NT-proBNP level Lower GFR Higher LVEF Higher NYHA class Lower KCCQ score                                                                                                           | • In control group, women had higher rates of HF hospitalization and lower rates of CV death  
  • Rate ratio for primary outcome was 0.73 (95% CI: 0.59–0.90) in women and 1.03 (95% CI: 0.84–1.25) in men with p interaction = 0.017, predominately related to HF hospitalization (33% RRR, p interaction = 0.005) |
| EMPEROR-PRESERVED   | 5988               | 44.7%    | Empagliflozin        | 40%        | Prespecified subgroup                                                     | —                                                                                                                                                                                                                                        | • No difference between women and men  
  • HR for male: 0.81 (95% CI: 0.69–0.96) and for female: 0.75 (95% CI: 0.64–0.92)                                                                                                                                         |
| DELIVER (2022)      | 6263               | 43.9%    | Dapagliflozin        | 40%        | Prespecified subgroup                                                     | —                                                                                                                                                                                                                                        | • No difference between women and men  
  • HR for male: 0.82 (95% CI: 0.71–0.96) and for female: 0.81 (95% CI: 0.67–0.97)                                                                                                                                         |

Summary of sex-specific results in recent HFpEF treatment trials, including TOPCAT, PARAGON-HF, and EMPEROR-PRESERVED.

TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with Aldosterone Antagonist; PARAGON-HF: Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction; EMPEROR-PRESERVED: Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction; EF: ejection fraction; CAD: coronary artery disease; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; LVEF: left ventricular ejection fraction; BP: blood pressure; BMI: body mass index; GFR: glomerular filtration rate; Hgb: hemoglobin; NYHA: New York Heart Association; KCCQ: Kansas City Cardiomyopathy Questionnaire; NT-proBNP: N-terminal pro brain natriuretic peptide; MRA: mineralocorticoid; HR: hazard ratio; CI: confidence interval; RRR: relative risk reduction.
traditional risk factors, unique pathophysiological consequences that put women at higher risk from these traditional risk factors, and distinct sex-specific effects. While women represent the majority of patients with HFpEF, there is still a lack of adequate representation in clinical trials. Given the heterogeneity of HFpEF, further work is needed to create more accurate risk stratification models that encompass both traditional and sex-specific risk markers. Additionally, we are yet to thoroughly understand the differences in pathophysiological mechanisms as well as responses to comorbidities between women and men.

Given these challenges, we propose a series of future directions to address the higher prevalence of HFpEF in women and improve outcomes:

- Existing evidence suggests that sex-specific miRNA networks may mediate the relationship between comorbidity-induced inflammatory activation and HFpEF pathogenesis in women. Future research on miRNA-induced mechanisms may shed light on unique pathways that contribute to HFpEF development in women.
- Improved mechanistic understanding of sex-specific inflammatory cascades and effects of sex hormones may enable greater precision of targeted therapies for women with HFpEF. Specifically, identification of novel circulating biomarkers related to tissue remodeling, inflammation, and neurohormonal regulation may refine risk prediction in women with HFpEF.
- Baseline sex differences in LV ejection fraction and steeper trajectories with age in women are well established, but diagnostic cutoffs remain sex-agnostic.88 We propose sex-specific diagnostic cutoffs in ejection fraction.8
- A preventive strategy should be adopted to decrease the rising incidence and prevalence of HFpEF in women.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contribution(s)

Gurleen Kaur: Conceptualization; Writing – original draft; Writing – review & editing.
Emily Lau: Conceptualization; Writing – original draft; Writing – review & editing.

Acknowledgements
None.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: E.L. is supported by the NIH K23-HL159243 and the American Heart Association (853922).

Competing interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials
Not applicable.

ORCID iD
Emily Lau https://orcid.org/0000-0001-9361-6397

References

1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 2022; 145: e153–e639.
2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6(3): 606–619.
3. Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J 2012; 33(14): 1734–1741.
4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145: e895–e1032.
5. Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4(4): 531–539.
6. Stolfo D, Uijl A, Vedin O, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. JACC Heart Fail 2019; 7(6): 505–515.
7. Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018; 39: 3439–3450.
8. Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation 2018; 138: 198–205.
9. Beale AL, Nanayakkara S, Segan L, et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed invasive hemodynamic and echocardiographic analysis. JACC Heart Fail 2019; 7(3): 239–249.
10. Sotomi Y, Hikoso S, Nakatani D, et al. Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc 2021; 10: e018574.
11. Tromp J, Shen L, Jhund PS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2019; 74: 601–612.
12. Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation* 2015; 131: 269–279.

13. Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. *Eur J Heart Fail* 2007; 9(1): 83–91.

14. Goyal P, Paul T, Almarzooq ZI, et al. Sex- and race-related differences in characteristics and outcomes of hospitalizations for heart failure with preserved ejection fraction. *J Am Heart Assoc* 2017; 6: e003330.

15. Ho JE, Enserro D, Brouwers FP, et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. *Circ Heart Fail* 2016; 9(6): e003116.

16. Eaton CB, Pettinger M, Rossouw J, et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multi racial cohort of postmenopausal women. *Circ Heart Fail* 2016; 9(10): e002883.

17. Daubert MA and Douglas PS. Primary prevention of heart failure in women. *JACC Heart Fail* 2019; 7: 181–191.

18. Suthahar N, Lau ES, Blaha MJ, et al. Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure. *J Am Coll Cardiol* 2020; 76: 1455–1465.

19. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. *New Engl J Med* 2002; 347: 305–313.

20. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. *Eur Heart J* 2013; 34(19): 1424–1431.

21. Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. *Circ Heart Fail* 2012; 5: 571–578.

22. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. *JACC Heart Fail* 2018; 6(8): 701–709.

23. Tromp J, Westenbrink BD, Ouwerkerk W, et al. Identifying pathophysiologic mechanisms in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol* 2018; 72: 1081–1090.

24. Karastergiou K, Smith SR, Greenberg AS, et al. Sex differences in human adipose tissues—the biology of pear shape. *Biol Sex Differ* 2012; 3: 13.

25. Ambikairajah A, Walsh E, Tabatabaei-Jafari H, et al. Fat mass changes during menopause: a metaanalysis. *Am J Obstet Gynecol* 2019; 221(5): 393.e50–409.e50.

26. Florijn BW, Bijkerk R, van der Veer EP, et al. Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women? *Cardiovasc Re* 2018; 114: 210–225.

27. Neeland JI, Gupta S, Ayers CR, et al. Relation of regional fat distribution to left ventricular structure and function. *Circ Cardiovasc Imaging* 2013; 6(5): 800–807.

28. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. *JACC Heart Fail* 2018; 6(8): 640–649.

29. Kannel WB, Hjortland M and Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974; 34(1): 29–34.

30. Paulus WJ and Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013; 62: 263–271.

31. Shenouda SM, Widdlansky ME, Chen K, et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. *Circulation* 2011; 124: 444–453.

32. Van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. *Circulation* 2012; 126: 830–839.

33. Galdersi M, Anderson KM, Wilson PW, et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). *Am J Cardiol* 1991; 68: 85–89.

34. Kim HL, Kim MA, Oh S, et al. Sex difference in the association between metabolic syndrome and left ventricular diastolic dysfunction. *Metab Syndr Relat Disord* 2016; 14(10): 507–512.

35. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. *JAMA* 1996; 275: 1557–1562.

36. Garavaglia GE, Messerli FH, Schmieder RE, et al. Sex differences in cardiac adaptation to essential hypertension. *Eur Heart J* 1989; 10(12): 1110–1114.

37. Kuch B, Muscholl M, Luchner A, et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. *J Hum Hypertens* 1998; 12(10): 685–691.

38. Gori M, Lam CS, Gupta DK, et al. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2014; 16(5): 535–542.

39. Higashi H, Okayama H, Saito M, et al. Relationship between augmentation index and left ventricular diastolic function in healthy women and men. *Am J Hypertens* 2013; 26(11): 1280–1286.

40. Tadic M, Cuspidi C, Plein S, et al. Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies. *J Clin Med* 2019; 8: 792.

41. Chester R, Sander G, Fernandez C, et al. Women have significantly greater difference between central and peripheral arterial pressure compared with men: the Bogalusa Heart Study. *J Am Soc Hypertens* 2013; 7(5): 379–385.

42. Kwak SJ, Melensovsky V and Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2014; 63: 2817–2827.

43. Elgendy IY and Pepine CJ. Heart failure with preserved ejection fraction: is ischemia due to coronary microvascular dysfunction a mechanistic factor? *Am J Med* 2019; 132(6): 692–697.

44. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J* 2018; 39: 840–849.

45. Sharma K, Al Rifai M, Ahmed HM, et al. Usefulness of coronary artery calcium to predict heart failure with preserved ejection fraction in men versus women (from the
multi-ethnic study of atherosclerosis). *Am J Cardiol* 2017; 120: 1847–1853.

46. Zakeri R, Chamberlain AM, Roger VL, et al. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. *Circulation* 2013; 128: 1085–1093.

47. Linssen GC, Rienstra M, Jaarsma T, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. *Eur J Heart Fail* 2011; 13(10): 1111–1120.

48. O’Neal WT, Sandesara P, Hammadah M, et al. Gender differences in the risk of adverse outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction. *Am J Cardiol* 2017; 119: 1785–1790.

49. Savarese G, Jonsson Å, Hallberg AC, et al. Prevalence of, associations with, and prognostic role of anaemia in heart failure across the ejection fraction spectrum. *Int J Cardiol* 2020; 298: 59–65.

50. Berry C, Poppe KK, Gamble GD, et al. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. *QJM* 2016; 109(6): 377–382.

51. Anand IS and Gupta P. Anaemia and iron deficiency in heart failure: current concepts and emerging therapies. *Circulation* 2018; 138: 80–98.

52. Lund LH, Donal E, Oger E, et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2014; 16: 992–1001.

53. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol* 2014; 64: 2281–2293.

54. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. *Circulation* 2012; 126: 65–75.

55. Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. *Am J Heart* 2012; 163(3): 430–437, 437.e1–437.e3.

56. Macdougall IC, Canuda B, de Francisco AL, et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. *Eur J Heart Fail* 2012; 14(8): 882–886.

57. Kajimoto K, Minami Y, Sato N, et al. Gender differences in anaemia and survival in patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. *Am J Cardiol* 2017; 120: 435–442.

58. Gökcü M, Karahan B, Erdöl C, et al. Left ventricular diastolic function assessment by tissue Doppler echocardiography in relation to hormonal replacement therapy in postmenopausal women with diastolic dysfunction. *Am J Ther* 2003; 10(2): 104–111.

59. Sabbatini AR and Kararigas G. Menopause-related estrogen decrease and the pathogenesis of HFrEF: JACC review topic of the week. *J Am Coll Cardiol* 2020; 75: 1074–1082.

60. Subramanya V, Zhao D, Ouyang P, et al. Sex hormone levels and change in left ventricular structure among men and post-menopausal women: the multi-ethnic study of atherosclerosis (MESA). *Maturitas* 2018; 108: 37–44.
78. O’Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2007; 115: 3111–3120.
79. Merrill M, Sweitzer NK, Lindenfeld J, et al. Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Fail 2019; 7(3): 228–238.
80. Faxén UL, Hage C, Donal E, et al. Patient reported outcome in HFpEF: sex-specific differences in quality of life and association with outcome. Int J Cardiol 2018; 267: 128–132.
81. Mauricio R, Patel KV, Agusala V, et al. Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial. Eur J Heart Fail 2019; 21(11): 1476–1479.
82. Lau ES, Cunningham T, Hardin KM, et al. Sex differences in cardiometabolic traits and determinants of exercise capacity in heart failure with preserved ejection fraction. JAMA Cardiol 2020; 5: 30–37.
83. Honigberg MC, Lau ES, Jones AD, et al. Sex differences in exercise capacity and quality of life in heart failure with preserved ejection fraction: a secondary analysis of the RELAX and NEAT-HFpEF trials. J Card Fail 2020; 26(3): 276–280.
84. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New Engl J Med 2019; 381: 1609–1620.
85. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation 2020; 141: 338–351.
86. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. New Engl J Med 2021; 385: 1451–1461.
87. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New Engl J Med 2022; 387: 1089–1098.
88. Chung AK, Das SR, Leonard D, et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation 2006; 113: 1597–1604.